Two new COVID-19 vaccines are set to arrive in the UK. As the country emerges from the lockdown, announcements were made recently about theModernaandNovavaxVaccines will increase confidence in vaccination adoption.
With more than 30 million first cans managed, the rollout is going well. Two vaccines are currently in use: Oxford / AstraZeneca and Pfizer / BioNTech.
The UK government aims to ensure that the entire adult population is vaccinated with at least one dose end of July. But lately the country has been hit by delays in expected deliveries. In April, the focus will be on second doses rather than vaccinating more people with their first doses. This has raised concerns about the vaccination program, which is still on track.
The two new vaccines will help with that. The Moderna vaccine won UK approval in January and is already widespread elsewhere. The Novavax vaccine is expected to file for UK approval soon after successful phase 3 studies.
While some of the AstraZeneca vaccine is made in the UK, the country relies on imports. A large proportion of vaccines administered in the UK are imported from India or the EU. While Government is relentless To achieve his goals, Minister of Health Matt Hancock has referred to vaccine supplies as “vaccine supplies.” lumpy ”.
A letter from NHS England On March 17th, the vaccination centers were informed that the offer should be reduced considerably from March 29th. Vaccination centers have been instructed to process as many adults over 50 as possible, use short-shelf inventory, and close online bookings.
A major reason for this move is the reduced supply of the AstraZeneca vaccine from India. An order for 10 million doses of vaccines was only partially fulfilled, with 5 million doses remaining in India. India has de facto an export ban imposed for vaccines, while the country is focusing on domestic vaccinations to fend off a new wave of infections.
However, export bans are not the only cause of uncertainty in the vaccine supply chain. The Serum Institute of India, the world’s largest vaccine manufacturer, also reported a shortage of materials Effects on production. This is not an isolated incident, and global agreement and coordination is needed to remove bottlenecks.
In addition, 1.7 million doses of the AstraZeneca vaccine had to be administered retested as part of ongoing quality assurance for product stability. While strict quality standards are essential and difficulties in increasing production on a global scale are not unexpected, there is an urgent need for alternatives.
The cavalry is coming
With countries struggling to ensure adequate supplies of vaccines, companies cannot ramp up production fast enough. Enter the Moderna vaccine. Dr. Anthony Fauci, Chief Medical Officer of the US President, said about the arrival of the vaccine there: ” The cavalry is coming ”.
In the UK, the immediate impact of Moderna will be limited, but limited. In total, only 17 million cans were ordered 500,000 are expected to arrive in April. This is enough to just cover an average day of vaccinations.
Novavax will be another valuable addition to the UK vaccine arsenal. Supplies for the UK market are made by FUJIFILM Diosynth Biotechnologies in Stockton-on teas.
Originally, the serum would have been sent to the EU to be filled into ready-to-use vials. But on March 29th, pharmaceutical company GlaxoSmithKline announced that it had reached an agreement in principle with Novavax and the UK Government Vaccines Taskforce. They will support the manufacture of up to 60 million doses of the Novavax COVID-19 vaccine candidate using a location in County Durham to ” fill and finish ”Instead of the EU. Deliveries are expected from June.
This ensures that Novavax manufacturing for the UK market is entirely based in the UK.
Boris Johnson is among the heads of state who have signed one international call for more common action recognize around the world that “no one is safe until everyone is safe”. Even so, in the face of global shortages and vaccine nationalism, domestic vaccine production will reassure many.
On March 29th some UK Blocking rules relaxed and residents in England are now allowed to meet in groups of six or two households that come together. The End of the shield for vulnerable patients has also started. Outdoor activities and sports have been resumed for the convenience of many. For those who received their vaccinations, there was reason to celebrate their “deconfination”. Some age groups are now having to wait longer than expected for their dose.
The expected arrival of two new vaccines may improve the morale of those concerned about the wait. The announcement of domestic production of Novavax has calmed the troublemakers Discussions about export bans.
However, we need to consider the complexities of vaccine supply chains. Essential ingredients Manufacturing process tools, including cell cultures, disposable tubing and specialty chemicals, bags and filters, are expected to continue to be imported.
There are other changes in the vaccination horizon that offer hope for people waiting to be vaccinated. AstraZeneca, Pfizer / BioNtec, and Moderna are all currently Modernization of your production facilities in Europe. New production facilities are approved and processes are expanded.
Coupled with working with GlaxoSmithKline to further develop the Novavax vaccine, this increase in production will bring some convenience to adults under 50 who are still waiting for their vaccine.
Liz Breen, Director of the Digital Health Enterprise Zone (DHEZ), University of Bradford, Healthcare Reader, University of Bradford and Sarah Schiffling, Lecturer for Supply Chain Management, Liverpool John Moore University